Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ß-oxidation

Sunmi Seok, Young Chae Kim, Sangwon Byun, Sunge Choi, Zhen Xiao, Naoki Iwamori, Yang Zhang, Chaochen Wang, Jian Ma, Kai Ge, Byron Kemper, Jongsook Kim Kemper

Research output: Contribution to journalArticle

Abstract

Jumonji D3 (JMJD3) histone demethylase epigenetically regulates development and differentiation, immunity, and tumorigenesis by demethylating a gene repression histone mark, H3K27-me3, but a role for JMJD3 in metabolic regulation has not been described. SIRT1 deacetylase maintains energy balance during fasting by directly activating both hepatic gluconeogenic and mitochondrial fatty acid ß-oxidation genes, but the underlying epigenetic and gene-specific mechanisms remain unclear. In this study, JMJD3 was identified unexpectedly as a gene-specific transcriptional partner of SIRT1 and epigenetically activated mitochondrial ß-oxidation, but not gluconeogenic, genes during fasting. Mechanistically, JMJD3, together with SIRT1 and the nuclear receptor PPARa, formed a positive autoregulatory loop upon fasting-activated PKA signaling and epigenetically activated ß-oxidation–promoting genes, including Fgf21, Cpt1a, and Mcad. Liver-specific downregulation of JMJD3 resulted in intrinsic defects in ß-oxidation, which contributed to hepatosteatosis as well as glucose and insulin intolerance. Remarkably, the lipid-lowering effects by JMJD3 or SIRT1 in diet-induced obese mice were mutually interdependent. JMJD3 histone demethylase may serve as an epigenetic drug target for obesity, hepatosteatosis, and type 2 diabetes that allows selective lowering of lipid levels without increasing glucose levels.

Original languageEnglish (US)
Pages (from-to)3144-3159
Number of pages16
JournalJournal of Clinical Investigation
Volume128
Issue number7
DOIs
StatePublished - Jul 2 2018

Fingerprint

Histone Demethylases
Fasting
Fatty Acids
Genes
Epigenomics
Histone Code
Lipids
Obese Mice
Glucose Intolerance
Liver
Cytoplasmic and Nuclear Receptors
Type 2 Diabetes Mellitus
Immunity
Carcinogenesis
Down-Regulation
Obesity
Insulin
Diet
Glucose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ß-oxidation. / Seok, Sunmi; Kim, Young Chae; Byun, Sangwon; Choi, Sunge; Xiao, Zhen; Iwamori, Naoki; Zhang, Yang; Wang, Chaochen; Ma, Jian; Ge, Kai; Kemper, Byron; Kemper, Jongsook Kim.

In: Journal of Clinical Investigation, Vol. 128, No. 7, 02.07.2018, p. 3144-3159.

Research output: Contribution to journalArticle

Seok, S, Kim, YC, Byun, S, Choi, S, Xiao, Z, Iwamori, N, Zhang, Y, Wang, C, Ma, J, Ge, K, Kemper, B & Kemper, JK 2018, 'Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ß-oxidation', Journal of Clinical Investigation, vol. 128, no. 7, pp. 3144-3159. https://doi.org/10.1172/JCI97736
Seok, Sunmi ; Kim, Young Chae ; Byun, Sangwon ; Choi, Sunge ; Xiao, Zhen ; Iwamori, Naoki ; Zhang, Yang ; Wang, Chaochen ; Ma, Jian ; Ge, Kai ; Kemper, Byron ; Kemper, Jongsook Kim. / Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ß-oxidation. In: Journal of Clinical Investigation. 2018 ; Vol. 128, No. 7. pp. 3144-3159.
@article{56a26c8405974470ae015180263d562b,
title = "Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid {\ss}-oxidation",
abstract = "Jumonji D3 (JMJD3) histone demethylase epigenetically regulates development and differentiation, immunity, and tumorigenesis by demethylating a gene repression histone mark, H3K27-me3, but a role for JMJD3 in metabolic regulation has not been described. SIRT1 deacetylase maintains energy balance during fasting by directly activating both hepatic gluconeogenic and mitochondrial fatty acid {\ss}-oxidation genes, but the underlying epigenetic and gene-specific mechanisms remain unclear. In this study, JMJD3 was identified unexpectedly as a gene-specific transcriptional partner of SIRT1 and epigenetically activated mitochondrial {\ss}-oxidation, but not gluconeogenic, genes during fasting. Mechanistically, JMJD3, together with SIRT1 and the nuclear receptor PPARa, formed a positive autoregulatory loop upon fasting-activated PKA signaling and epigenetically activated {\ss}-oxidation–promoting genes, including Fgf21, Cpt1a, and Mcad. Liver-specific downregulation of JMJD3 resulted in intrinsic defects in {\ss}-oxidation, which contributed to hepatosteatosis as well as glucose and insulin intolerance. Remarkably, the lipid-lowering effects by JMJD3 or SIRT1 in diet-induced obese mice were mutually interdependent. JMJD3 histone demethylase may serve as an epigenetic drug target for obesity, hepatosteatosis, and type 2 diabetes that allows selective lowering of lipid levels without increasing glucose levels.",
author = "Sunmi Seok and Kim, {Young Chae} and Sangwon Byun and Sunge Choi and Zhen Xiao and Naoki Iwamori and Yang Zhang and Chaochen Wang and Jian Ma and Kai Ge and Byron Kemper and Kemper, {Jongsook Kim}",
year = "2018",
month = "7",
day = "2",
doi = "10.1172/JCI97736",
language = "English (US)",
volume = "128",
pages = "3144--3159",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ß-oxidation

AU - Seok, Sunmi

AU - Kim, Young Chae

AU - Byun, Sangwon

AU - Choi, Sunge

AU - Xiao, Zhen

AU - Iwamori, Naoki

AU - Zhang, Yang

AU - Wang, Chaochen

AU - Ma, Jian

AU - Ge, Kai

AU - Kemper, Byron

AU - Kemper, Jongsook Kim

PY - 2018/7/2

Y1 - 2018/7/2

N2 - Jumonji D3 (JMJD3) histone demethylase epigenetically regulates development and differentiation, immunity, and tumorigenesis by demethylating a gene repression histone mark, H3K27-me3, but a role for JMJD3 in metabolic regulation has not been described. SIRT1 deacetylase maintains energy balance during fasting by directly activating both hepatic gluconeogenic and mitochondrial fatty acid ß-oxidation genes, but the underlying epigenetic and gene-specific mechanisms remain unclear. In this study, JMJD3 was identified unexpectedly as a gene-specific transcriptional partner of SIRT1 and epigenetically activated mitochondrial ß-oxidation, but not gluconeogenic, genes during fasting. Mechanistically, JMJD3, together with SIRT1 and the nuclear receptor PPARa, formed a positive autoregulatory loop upon fasting-activated PKA signaling and epigenetically activated ß-oxidation–promoting genes, including Fgf21, Cpt1a, and Mcad. Liver-specific downregulation of JMJD3 resulted in intrinsic defects in ß-oxidation, which contributed to hepatosteatosis as well as glucose and insulin intolerance. Remarkably, the lipid-lowering effects by JMJD3 or SIRT1 in diet-induced obese mice were mutually interdependent. JMJD3 histone demethylase may serve as an epigenetic drug target for obesity, hepatosteatosis, and type 2 diabetes that allows selective lowering of lipid levels without increasing glucose levels.

AB - Jumonji D3 (JMJD3) histone demethylase epigenetically regulates development and differentiation, immunity, and tumorigenesis by demethylating a gene repression histone mark, H3K27-me3, but a role for JMJD3 in metabolic regulation has not been described. SIRT1 deacetylase maintains energy balance during fasting by directly activating both hepatic gluconeogenic and mitochondrial fatty acid ß-oxidation genes, but the underlying epigenetic and gene-specific mechanisms remain unclear. In this study, JMJD3 was identified unexpectedly as a gene-specific transcriptional partner of SIRT1 and epigenetically activated mitochondrial ß-oxidation, but not gluconeogenic, genes during fasting. Mechanistically, JMJD3, together with SIRT1 and the nuclear receptor PPARa, formed a positive autoregulatory loop upon fasting-activated PKA signaling and epigenetically activated ß-oxidation–promoting genes, including Fgf21, Cpt1a, and Mcad. Liver-specific downregulation of JMJD3 resulted in intrinsic defects in ß-oxidation, which contributed to hepatosteatosis as well as glucose and insulin intolerance. Remarkably, the lipid-lowering effects by JMJD3 or SIRT1 in diet-induced obese mice were mutually interdependent. JMJD3 histone demethylase may serve as an epigenetic drug target for obesity, hepatosteatosis, and type 2 diabetes that allows selective lowering of lipid levels without increasing glucose levels.

UR - http://www.scopus.com/inward/record.url?scp=85049839155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049839155&partnerID=8YFLogxK

U2 - 10.1172/JCI97736

DO - 10.1172/JCI97736

M3 - Article

C2 - 29911994

AN - SCOPUS:85049839155

VL - 128

SP - 3144

EP - 3159

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -